Protective effects of irbesartan and alpha lipoic acid in STZ-induced diabetic nephropathy in rats

Renal Failure

Volumn 32, Issue 4, 2010, Pages 498-505

  Kanter, Mehmet ^a   Sen, Saniye ^a   Donmez, Salim ^a   Aktas, Cevat ^b   Ustundag, Sedat ^a   Erboga, Mustafa ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b NAMIK KEMAL UNIVERSITY   (Turkey)

Author keywords

Alpha lipoic acid; Diabetic nephropathy; INOS; Irbesartan; TGF 1

Indexed keywords

IRBESARTAN; STREPTOZOCIN; THIOCTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE BASEMENT MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES;

ANIMALS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEMALE; IMMUNOENZYME TECHNIQUES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TETRAZOLES; THIOCTIC ACID; TRANSFORMING GROWTH FACTOR BETA;

EID: 77952174536     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003646360     Document Type: Article

References (40)

1. Rohrbach DH, Wagner CW, Star VL, Martin GR, Brown KS, Yoon JW. Reduced synthesis of basement membrane heparan sulfate proteoglycan in streptozotocin induced diabetic mice. J Biol Chem. 1983;258:11672-11677.
2. Ihm CG, Lee GS, Nast CC, et al. Early increased renal procollagen alpha 1(IV) mRNA levels in streptozotocin induced diabetes. Kidney Int. 1992;41:768-777.
3. Reddi AS, Nimmagadda VR, Arora R. Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension. Hypertension. 2001;37:1273-1278.
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
6. Carreau JP. Biosynthesis of lipoic acid via unsaturated fatty acids. Methods Enzymol. 1979;62:152-158.
7. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
8. Melhem MF, Craven PA, De Rubertis FR. Effects of dietary supplementation of a-lipoic acid on early glomerular injury in diabetes. J Am Soc Nephrol. 2001;12:124-133.
9. Kanter M, Meral I, Yener Z, Ozbek H, Demir H. Partial regeneration/ proliferation of the ß-cells in the islets of Langerhans by Nigella sativa L. in streptozotocin-induced diabetic rats. Tohoku J Exp Med. 2003;201:213-219.
10. Kanter M, Coskun O, Korkmaz A, Oter S. Effects of Nigella sativa on oxidative stress and ß-cell damage in streptozotocininduced diabetic rats. Anat Rec. 2004;279:685-691.
11. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
12. Collart F. Kidney failure, proteinuria, and diabetic nephropathy. Rev Med Brux. 2003;24:A257-A262.
13. Kreisberg JI, Garoni JA, Radnik R, Ayo SH. High glucose and TGFb1 stimulate fibronectin gene expression through a cAMP response element. Kidney Int. 1994;46:1019-1024.
14. Attisano L, Wrana JL. Signal transduction by members of the transforming growth factor-b superfamily. Cytokine Growth Factor Rev. 1996;7:327-339.
15. August P, Suthanthiran M. Transforming growth factor b signaling, vascular remodeling, and hypertension. N Engl J Med. 2006;354:2721-2723.
16. Border WA, Noble NA. Transforming growth factor b in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
17. Hayashida T, Poncelet AC, Hubchak SC, Schnaper HW. TGF-b1 activates MAP kinase in human mesangial cells: A possible role in collagen expression. Kidney Int. 1999;56: 1710-1720.
18. Border WA, Noble NA. Cytokines in kidney disease: The role of transforming growth factor b. Am J Kidney Dis. 1993;22: 105-113.
19. Poncelet AC, Schnaper HW. Regulation of human mesangial cell collagen expression by transforming growth factor-b1. Am J Physiol. 1998;275:F458-F466.
20. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A. 1993;90:1814-1818.
21. Yagi K, Kim S, Wanibuchi H, Yamashita T, Yamamura Y, Iwao H. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long-Evans Tokushima fatty rats. Hypertension. 1997;29:728-735.
22. Shankland SJ, Scholey JW. Expression of transforming growth factor b1 during diabetic renal hypertrophy. Kidney Int. 1994;46:430-442.
23. Hellmich B, Schellner M, Schatz H, Pfeiffer A. Activation of transforming growth factor-b1 in diabetic kidney disease. Metabolism. 2000;49:353-359.
24. Kreisberg JI, Ayo SH. The glomerular mesangium in diabetes mellitus. Kidney Int. 1993;43:109.
25. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 1999;56:1627-1637.
26. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int. 2000;58:S93-S98.
27. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
28. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-coverting enzyme inhibition and angiotensin receptor antagonist in diabetic spontaneously hypertensive rats. Clin Sci. 2001;100:591-599.
29. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-287.
30. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides. 2005;26:1401-1409.
31. Song KH, Lee WJ, Koh JM, et al. Alpha-lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Commun. 2005;326:197-202.
32. Lee WJ, Song KH, Koh EH, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332:885-891.
33. Kim MS, Park JY, Namkoong C, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med. 2004;10:727-733.
34. Melhem MF, Craven PA, Liachenko J, DeRubertis FR. Alphalipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol. 2002;13:108-116.
35. Morcos M, Borcea V, Isermann B, et al. Effect of a-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: An exploratory study. Diabetes Res Clin Pract. 2001;52:175-183.
36. Budisavljevic MN, Hodge L, Barber K, et al. Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. Am J Physiol Renal Physiol. 2003;285: F1138-F1148.
37. Oksala NK, Lappalainen J, Laaksonen DE, et al. Alpha-lipoic acid modulates heat shock factor-1 expression in streptozotocininduced diabetic rat kidney. Antioxid Redox Signal. 2007; 9:497-506.
38. Ishii N, Patel KP, Lane PH, et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol. 2001;12(8):1630-1639.
39. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol. 2000;11(1):71-79.
40. Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol. 2009;29:274-282.